Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Alexander Gruze"'
Autor:
Karoline V. Gleixner, Matthias Mayerhofer, Karoline Sonneck, Alexander Gruze, Puchit Samorapoompichit, Christian Baumgartner, Francis Y. Lee, Karl J. Aichberger, Paul W. Manley, Doriano Fabbro, Winfried F. Pickl, Christian Sillaber, Peter Valent
Publikováno v:
Haematologica, Vol 92, Iss 11 (2007)
Background and Objectives In a majority of all patients with systemic mastocytosis (SM) including those with mast cell leukemia (MCL), neoplastic mast cells (MC) display the D816V-mutated variant of KIT. The respective oncoprotein, KIT D816V, exhibit
Externí odkaz:
https://doaj.org/article/430b7f84199e49c69294d2146859da51
Autor:
Peter Valent, Christian Sillaber, Winfried F. Pickl, Matthias Mayerhofer, Sabine Cerny-Reiterer, Emir Hadzijusufovic, Renata A. Meyer, Alexander Gruze, Barbara Peter, Veronika Ferenc, Karoline V. Gleixner
Supplementary Figure Legends 1-2 from Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9204813a4bb4bc978aea1eed22bda2a1
https://doi.org/10.1158/0008-5472.22386731.v1
https://doi.org/10.1158/0008-5472.22386731.v1
Autor:
Peter Valent, Christian Sillaber, Winfried F. Pickl, Matthias Mayerhofer, Sabine Cerny-Reiterer, Emir Hadzijusufovic, Renata A. Meyer, Alexander Gruze, Barbara Peter, Veronika Ferenc, Karoline V. Gleixner
Supplementary Figures 1-2 from Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f0fbc7b137b01d47f79d9b54190b379
https://doi.org/10.1158/0008-5472.22386728.v1
https://doi.org/10.1158/0008-5472.22386728.v1
Autor:
Peter Valent, Christian Sillaber, Winfried F. Pickl, Matthias Mayerhofer, Sabine Cerny-Reiterer, Emir Hadzijusufovic, Renata A. Meyer, Alexander Gruze, Barbara Peter, Veronika Ferenc, Karoline V. Gleixner
In most patients with chronic myeloid leukemia (CML), the disease can be kept under control using the BCR/ABL kinase inhibitor imatinib. Nevertheless, resistance or intolerance to imatinib and other BCR/ABL inhibitors may occur during therapy. Theref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::064519f8922cd02485c8a465d23f2c3a
https://doi.org/10.1158/0008-5472.c.6501623.v1
https://doi.org/10.1158/0008-5472.c.6501623.v1
Autor:
Karoline V. Gleixner, Alexander Gruze, Renata A. Meyer, Peter Valent, Veronika Ferenc, Barbara Peter, Emir Hadzijusufovic, Winfried F. Pickl, Matthias Mayerhofer, Christian Sillaber, Sabine Cerny-Reiterer
Publikováno v:
Cancer Research. 70:1513-1523
In most patients with chronic myeloid leukemia (CML), the disease can be kept under control using the BCR/ABL kinase inhibitor imatinib. Nevertheless, resistance or intolerance to imatinib and other BCR/ABL inhibitors may occur during therapy. Theref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bab3dc31047b7f819d86453c00effb0
https://doi.org/10.1158/0008-5472.can-09-2181
https://doi.org/10.1158/0008-5472.can-09-2181
Autor:
E. Lackner, R. Panzer-Grumayer, Hiroshi Maeda, Peter Valent, Sabine Cerny-Reiterer, A. Vales, Christoph C. Zielinski, Matthias Mayerhofer, Alexander Gruze, Gregor Hörmann, Christian Sillaber, Brigitte Marian, Harald Herrmann, Arun K. Iyer, Emir Hadzijusufovic, Karoline V. Gleixner, Maria Theresa Krauth, Winfried F. Pickl
Publikováno v:
Current Cancer Drug Targets. 9:675-689
Heat shock protein 32 (Hsp32), also known as heme oxygenase-1 (HO-1), is a stress-related anti-apoptotic molecule, that has been implicated in enhanced survival of neoplastic cells and in drug-resistance. We here show that Hsp32 is expressed in most
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67dcf1a86de07cb44e513aa9fc4332d4
https://doi.org/10.2174/156800909789057024
https://doi.org/10.2174/156800909789057024
Autor:
Keiryn L. Bennett, Winfried F. Pickl, Veronika Ferenc, Lily L. Remsing Rix, Christian Sillaber, Barbara Peter, Puchit Samorapoompichit, Harald Esterbauer, Christian Baumgartner, Alexander Gruze, Giulio Superti-Furga, Karoline V. Gleixner, Francis Y. Lee, Peter Valent
Publikováno v:
Experimental Hematology. 36:1244-1253
Objective Chronic eosinophilic leukemia (CEL) is a myeloproliferative disorder characterized by molecular and/or cytogenetic evidence of clonality of eosinophils, marked eosinophilia, and organ damage. In many patients, the transforming mutation FIP1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2984a8497a66cd8e0fb1193c758b1364
https://doi.org/10.1016/j.exphem.2008.04.017
https://doi.org/10.1016/j.exphem.2008.04.017
Autor:
Alexandra Böhm, Harald Esterbauer, Oskar A. Haas, Peter Valent, Winfried F. Pickl, W. R. Sperr, Alexander Gruze, Christian Sillaber, Karl J. Aichberger, Michael Pfeilstöcker, A. Vales, Matthias Mayerhofer
Publikováno v:
European Journal of Clinical Investigation. 38:43-52
Background Recent data suggest that the mammalian target of rapamycin (mTOR) is involved in the regulation of growth of neoplastic cells in chronic myeloid leukaemia (CML). Patients and methods We treated six patients with imatinib-resistant CML in h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c06efd6f8e84bc3c6e2db0636c88a045
https://doi.org/10.1111/j.1365-2362.2007.01892.x
https://doi.org/10.1111/j.1365-2362.2007.01892.x
Autor:
Emir Hadzijusufovic, Matthias Mayerhofer, Puchit Samorapoompichit, Laura Rebuzzi, Karoline V. Gleixner, Alexander Gruze, Christian Sillaber, Karoline Sonneck, Vilma Yuzbasiyan-Gurkan, Winfried F. Pickl, Michael Willmann, Anja Vales, Michael Kneidinger, Tuddow Thaiwong, Peter Valent
Publikováno v:
Experimental Hematology. 35:1510-1521
Aggressive mast cell (MC) tumors are hematopoietic neoplasms characterized by uncontrolled growth of MC and resistance to conventional drugs. In most cases, the tyrosine kinase (TK) receptor KIT is involved in malignant cell growth. Therefore, severa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e824e44bcb2f2ee796cd8bdc4a3a4dc
https://doi.org/10.1016/j.exphem.2007.06.005
https://doi.org/10.1016/j.exphem.2007.06.005
Autor:
Doriano Fabbro, Alexandra Böhm, Winfried F. Pickl, Karoline V. Gleixner, Karoline Sonneck, Peter Valent, Matthias Mayerhofer, Karl J. Aichberger, Christian Sillaber, Sophia Derdak, Paul W. Manley, Puchit Samorapoompichit, Alexander Gruze
Publikováno v:
Blood. 107:752-759
In most patients with systemic mastocytosis (SM), including aggressive SM and mast cell leukemia (MCL), neoplastic cells express the oncogenic KIT mutation D816V. KIT D816V is associated with constitutive tyrosine kinase (TK) activity and thus repres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bde5440057cfc8b352b00f5a3a57c9b6
https://doi.org/10.1182/blood-2005-07-3022
https://doi.org/10.1182/blood-2005-07-3022